

Preparation for Animal Models of Osteoporosis: a Systematic Review

Panyun Mu

Chengdu University of Traditional Chinese Medicine Affiliated Hospital <https://orcid.org/0000-0002-8431-2583>

Peihua Qu

Chengdu University of Traditional Chinese Medicine Affiliated Hospital

Yulin Li

Chengdu University of Traditional Chinese Medicine

Jie Feng

Chengdu University of Traditional Chinese Medicine Affiliated Hospital

Xu Ma

Chengdu University of Traditional Chinese Medicine Affiliated Hospital

Feng Xiong

Chengdu University of Traditional Chinese Medicine Affiliated Hospital

Yimei Hu (✉ huyimei@cdutcm.edu.cn)

Chengdu University of Traditional Chinese Medicine Affiliated Hospital

Research

Keywords: Animal model, Ovariectomy, Primary osteoporosis, Secondary Osteoporosis

Posted Date: September 14th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-832368/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Background: it is of great significance for clinical diagnosis, prevention and treatment of osteoporosis to deeply understand the pathogenesis and development process of osteoporosis through animal models of osteoporosis. This systematic review aim to summarize the modeling methods of osteoporosis, reveal the current situation and progress of animal models of osteoporosis, and compare the advantages and disadvantages of various modeling methods, so as to provide reference for clinical research.

Methods: CNKI, CBM database, VIP database, Wanfang database, PubMed database and EMBASE database were searched by computer from the database establishment to December 2020 with the key words of "animal model; osteoporosis" in Chinese and English respectively. The literatures were screened according to inclusion and exclusion criteria. The methods of osteoporosis modeling, the improvement of the methods and the advantages and disadvantages of each method are summarized.

Discussion: a total of 9303 related literatures were collected, and 112 eligible literatures were included. The establishment of an appropriate animal model is the key to the etiology, pathophysiology and drug therapy of osteoporosis. As the causes and pathophysiological changes of different types of OP have their own characteristics, the modeling methods are also different. Therefore, different modeling methods and experimental animals should be selected according to different experimental requirements.

Systematic review registration: No

Introduction

Osteoporosis is a slow progressing disease and characteristics are the deterioration of bone tissue, loss of bone mass, bone fragility and increasing fracture risk¹⁻³. Osteoporosis usually has no obvious symptoms, with little or no trauma in some cases, unless it deteriorates into a fracture⁴. Bone fractures occur every three seconds as a result of osteoporosis, and spinal and hip fractures cause a large number of disability(4.48 million in 1990)⁵ and morbidity worldwide⁶.

Osteoporosis is generally classified as primary or secondary. Primary disease is due to the sudden decrease of sex hormones and physiological degenerative changes caused by age, including juvenile idiopathic osteoporosis. Postmenopausal and senile osteoporosis are the most prevalent types in humans. Secondary osteoporosis, which is about 10% of the total number of cases, can be induced by diseases or drug factors, such as endocrine and metabolic diseases (diabetes and hyperthyroidism), kidney diseases, liver diseases and gastrointestinal pathologies. Drugs can induce osteoporosis, including long-term high-dose heparin, immunosuppressants, antiepileptics and glucocorticoids. Endocrine disorders, lifestyle factors and long-term immobilisation are also causes of osteoporosis^{7,8}.

It is essential to conduct preclinical studies using animal models that mimic the relevant features of human disease processes. Animal models can play a very important role in the study of osteoporosis. The pathogenesis and pathological mechanisms of osteoporosis have independent characteristics and animal models of osteoporosis therefore vary. Proper study of osteoporosis using animal models will enhance understanding of the mechanisms of many treatment methods and allow the development of preventive and therapeutic drugs.

Data And Methods

2.1 Data Sources and Searches

The CNKI, Wanfang, VIP, Web of Science, PubMed and EMBASE databases were searched. The key words were osteoporosis and animal model in both Chinese and English. The retrieval time was from the establishment of the database to December 2020.

2.2 Inclusion and exclusion criteria

The inclusion criteria were: 1) the content of the literature was closely related to the subject of this study; 2) the articles were on animal models of osteoporosis; and 3) the articles described animal experiments. The exclusion criteria were: 1) repetitive and obsolete articles unrelated to the content of this study; 2) studies employing non-simple animal modelling; and 3) conference abstracts, comments, narrative comments and case reports.

2.3 Study Selection

Two reviewers independently screened the titles, abstracts and full-text for inclusion. Differences were resolved by consensus through consultation. A third reviewer was consulted if there were any unresolved discrepancies between the reviewers at any stage in the article selection process. Next, data extraction was conducted independently by the two reviewers, and the results of data extraction were compared again.

2.4 Data Abstraction and Quality Assessment

Data extraction was done back-to-back by the two reviewers using a spreadsheet to extract the following data: first author, publication date of the article, country, selected animals, modelling methods, bone mineral density (BMD) measurement locations and methods, experimental observation time, detection indicators and other factors. (Fig. 1. Flowchart of Literature Selection)

Results Of The Included Data

3.1 Search Results

The process of selecting the studies is described in Fig. 1. We retrieved 9,303 records in our search. After reviewing the abstracts and full texts, we included 112 studies. Among them, 53 were from Chinese databases and 59 were from English databases. The most common method of modelling was ovariectomy for females and testicle removal was performed in males⁹⁻²¹. The second method was the animal model of castration combined with drugs^{1 22-35}. A few other modelling methods, such as drug modelling alone^{28 36-43}, nutritional deficiency modelling⁴⁴⁻⁴⁸, disuse modelling^{16 49 50} and gene knockout modelling⁵¹⁻⁵⁶ were used in the retrieved studies. (Table 1. Table of general characteristics of the included English studies)

3.2 Selection of experimental animals for research model

It is very important to select the correct osteoporosis model animal. Different osteoporosis models, including animal species and human bone tissues, have different histological and biological metabolism characteristics. Measurements of basic bone mass vary for different ages and genders, and choosing the animal species for an osteoporosis model is very strict. At present, the commonly used animals include rats, mice, dogs, sheep, rabbits, pigs and primates⁵⁷⁻⁶¹. Rodents (including rats and mice) have been used in over 60% of the studies, followed by sheep and rabbits, according to the results of our survey. Other non-human primates, such as pigs and dogs, have also been used, but in relatively small numbers.

The rat is the most frequently used laboratory animal for studying osteoporosis and it has become the most used and mature model animal for osteoporosis. Rodents are often chosen for models because they are inexpensive and easy to maintain, grow quickly, have a relatively short lifespan, have good skeletal characteristics, and are widely available. Rodents have many similarities with humans, including their genomes⁶². Bone loss occurs with age, a similar distribution of cancellous bone, a high bone conversion rate after ovariectomy, decrease in intestinal calcium absorption, and a similar response to sex hormones^{45 63}.

Because of the clear understanding of the mouse genome, mice have become a common experimental animal in the field of bone mass gene control. Mice are often used to study the genetic factors of bone metabolism, importing or knocking out target genes, and observing phenotype and pathological changes. Mice are primary experimental model animals in the study of influential genetic factors on peak bone mass and age-related bone loss⁶². However, the disadvantages are: the epiphysis closure is slow and the bone reconstruction cycle is shorter than that of humans, which may interfere with the experimental results. Because ovariectomy does not cause brittle fractures, it is not suitable for the study of cortical bone changes after ovariectomy. The life cycle of rats is short and the blood volume is small so it is often impossible to take blood and biopsy samples. The biological cycle of rodents is significantly different from that of humans and this may produce errors in experiments. These issues draw attention to the need for models that more closely mimic humans⁶⁴. The lack of a Haversian reconstruction system and low activity of cortical reconstruction is not suitable for evaluating drugs promoting the role of Haversian reconstruction^{63 65}.

Compared with rodents, adult rabbits have obvious Haversian system reconstruction ability, a faster bone turnover rate¹⁶ and earlier epiphyseal closure (usually 6–8 months)⁷⁶⁶. According to the results of the included literature, rabbits have been used more often for ovariectomised, glucocorticoid and ovariectomised + glucocorticoid osteoporosis animal modelling¹⁶¹⁷²⁷²⁸³². Other animals, such as sheep, pigs, dogs⁶² and non-human primates also have a Haversian reconstruction system, and non-human primates are genetically closer to humans and have similar oestrus cycles⁶⁴. However, they are expensive²²⁶⁷, difficult to manage³¹⁵⁷, and hormonal changes have little impact on bone loss¹⁰⁶¹, so they are not used in models of osteoporosis.

Ideal experimental animal models would include absolute replication of human diseases. Unfortunately, this goal has not been achieved in the study of osteoporosis. Rats, mice, dogs, monkeys and apes are the main animals that have been used to simulate osteoporosis. Each species has its own advantages and disadvantages and not one of the experimental animal species includes all risk factors associated with an osteoporosis model⁶².

3.3 the basis for judging the effect of the modeling method

Since the lumbar spine, femur and tibia are the most common clinical fracture sites, most experiments have measured the BMD and bone mineral content (BMC) in these bones. The main measurement method is scanning with a dual-energy X-ray (DXA) instrument. Next, bone histometrics, biochemical parameters of blood samples (e.g. calcium and phosphorus), and bone biomechanics indexes have been determined. For postmenopausal osteoporosis, because the incidence of this type of osteoporosis is related to a decrease in oestrogen, the estradiol can be increased when comparing various indicators. All the above indicators can reflect the osteoporosis situation in animals from different aspects. It is necessary to comprehensively analyse a variety of indicators to achieve a comprehensive judgement on modelling effects.

3.4 Common animal models

3.4.1 Primary osteoporosis model

(1) Postmenopausal osteoporosis model (PMOP)

The OVX rat model is a classic model of PMOP⁶⁸, and it has been widely adopted to mimic oestrogen-deficiency-induced bone loss¹⁸. OVX can induce a decrease in oestrogen levels and increase the recruitment, differentiation and survival of osteoclasts so that bone resorption exceeds bone formation, which eventually leads to osteoporosis⁷.

In this model, bilateral ovaries are resected in a sterile environment, which results in a rapid decrease of oestrogen, enhanced bone turnover and increased bone resorption, resulting in osteoporosis⁶⁹. The bone mass loss after modelling was mainly trabecular bone loss, which is similar to the bone loss in

postmenopausal women. The Food and Drug Administration (FDA) has suggested that rats aged 6–10 months should be used to establish the model, which is usually 12 weeks or longer after castration⁷⁰. Surgical castration has been widely used because of its single modelling factor, definite modelling effect, good repeatability, high reliability of experimental results, and it can accurately reflect the cause of oestrogen decline, which successfully simulates the characteristics of postmenopausal osteoporosis bone metabolism.

However, there are still some controversies. First, oestrogen levels in animals suddenly and rapidly decrease after oophorectomy, while oestrogen decreases are long and slow processes in the natural course of disease, and ovarian stromal cells in postmenopausal women still have some endocrine function. Second, surgical castration itself is traumatic, which may cause a negative nitrogen balance, stress response and electrolyte disorder, which may affect the detection of indicators. Third, ovarian resection may lead to weight gain in rats, and weight gain may partially protect against bone loss. Finally, when oestrogen replacement therapy was studied in a castrated rat model, the fertility status of the rats affected the experimental results.

In addition, the removal of male testis can also be used to construct an osteoporosis model. These models have been used in the study of basic theory and drug intervention in male osteoporosis and significant results have been achieved. However, due to the continuous growth of the adult male epiphysis after 30 months, the experimental results using male rats are not widely accepted by scholars.

The effect of OVX on bone is not consistent in different bone sites⁷¹. Loss in long bones, including the tibia, femur, humerus and ulna, was reported at 36 weeks after ovariectomy (75.0%, 70.4%, 64.9% and 57.1%, respectively), compared with that of the lumbar spine and iliac bone (36.6% and 51.6%, respectively)¹⁸. In addition, only the ulna, femur and tibia showed significant bone loss at four weeks after OVX, indicating that these areas were more sensitive to OVX¹⁸. Also, OVX-induced bone loss is more severe and observed earlier in the proximal tibia than in the lumbar spine or femur, so short-term studies of the proximal tibia are recommended⁷¹. The use of rabbits^{16 17}, rodents (rats and mice)^{11–13 18 21}, sheep¹⁵ and non-human primates as animal models of OVX osteoporosis is recommended. We prefer rabbits and rats for reasons of economics, experiment time and animal ethics.

(2) Senile osteoporosis model (SAM)

Primary osteoporosis includes postmenopausal osteoporosis and senile osteoporosis. In both males and females, the loss of cancellous bone (also known as trabeculae) begins at thirty years old and there is rapid loss during menopause. On the other hand, most cortical bone loss occurs at 10 years after menopause due to cortical thinning and increased cortical porosity^{60 71}. Bones in most mammals are thought to deteriorate with age, but in animals commonly used in biological research, age-related bone loss is only well documented in crab-eating monkeys⁶⁴, sheep (6 ~ 10 years old)⁷², rats and mice^{73–77}.

Rats typically live two to three years, with bone mass peaking at 4–8 months of age and then declining with age⁷⁸. Watanabe et al.⁷⁸ introduced several classic models of age-related osteoporosis in which the strains of mice were C57BL/6, BALB/C and senescence accelerated mice (SAM)^{74–76}. However, inbred mice (C57BL/6 and BALB/C) were prone to die of cancer⁷⁹, which affected the process of subsequent experiments. Takeda⁸⁰ and his colleagues established a SAM composed of SAMP and SAMR series. Compared with normal mice, SAMR and SAMP had accelerated ageing. Senescence-accelerated mouse prone 6 (SAMP6) was reported as the first mouse model of spontaneous senile osteoporosis⁷⁶. Only one of the articles included in our study used SAMP6 rats as model animals⁵¹. Azuma et al.⁷⁴ found that SAMP6 mice have many morphologic and molecular features that mimic human bone ageing, and they are considered as a useful experimental model for the spontaneity of age-related osteoporosis⁷⁶.

(3) Gene recombination animal model of osteoporosis

Developments in genetic technology have made it possible to create animal models with specific genetic traits by silencing or knocking out a particular gene. Gene technology used in osteoporosis modelling mainly includes gene knockout technology and gene mutation technology. Most of the mice treated with gene technology were used to study primary osteoporosis. For example, osteoprotegerin knockout mice (OPG-/-)⁸¹ were used to study postmenopausal osteoporosis, and gene mutation mice SAMP6 were used to study ageing osteoporosis⁷⁵. Some studies reported that various genes, cytokines and pathways were associated with BMD, osteoporosis, or fractures^{82–84}. Compared with the classical castrated rat model, SAMP6 has obvious advantages. It has a clear genetic background and avoids interference from the external environment as much as possible. Osteoporosis can occur in the early postnatal period, which can shorten the experiment time. Without surgical intervention, the negative nitrogen balance of the model animals did not occur, and there was little influence on the internal environment related to sex hormones *in vivo*. However, its high price, complicated process and technical difficulty undoubtedly limit its application.

3.4.2 Secondary osteoporosis model

(1) Glucocorticoid Osteoporosis (GIOP)

Due to the wide application of glucocorticoids in the clinic, the incidence of osteoporosis caused by glucocorticoids is second only to postmenopausal osteoporosis and senile osteoporosis, and ranks first in secondary osteoporosis. Induction methods include gavage, oral administration and intramuscular injection. The treatment drugs usually mediate prednisone; e.g. methylprednisone and occasionally high-potency dexamethasone. Significant bone loss occurs as early as 10 days and as late as 48 weeks after use. However, this model is not fully suitable for evaluating the inhibitory effects of drugs on bone resorption, because glucocorticoid-induced osteoporosis is not consistent with the pathogenesis and course of primary osteoporosis. Rats, mice, rabbits⁸⁵, sheep²⁶, pigs⁴¹ and dogs can be used as models in this method. The rabbits are sensitive to glucocorticoid induction, and the modelling time is short³². Rats are usually the dominant model and can be successfully modelled after 5–6 weeks.

(2) Retinoic Acid (RA)

Retinoic acid, a derivative of vitamin A, can activate osteoclasts and promote bone resorption, but it does not inhibit the activity of osteoblasts and has no obvious effect on bone formation and the mineralisation process of the bone matrix. As a result, bone remodelling is in a negative balance state with bone resorption greater than bone formation, and this ultimately leads to osteoporosis in animals. Although the pathogenic factors of this model are different from the clinical factors, it is similar to humans regarding symptoms, histomorphological manifestations and bone responses to oestrogen. In addition, it is a commonly used modelling method for acute osteoporosis in rats due to its short modelling time^{86,87}. Generally, oral administration of retinoic acid or a gavage of 70–105 mg/kg for two consecutive weeks can successfully establish an osteoporosis model, which has good short-term effects but poor long-term effects. This model has the advantages of convenient operation, a high success rate and typical symptoms⁸⁶, so it is widely used in the research and development of new drugs.

(3) Alcoholic osteoporosis model

The abuse of alcohol is one of the most important lifestyle risk factors for osteoporosis. Microanatomical changes in the skeletons of alcohol-dependent rats were later identified in human alcoholics, providing evidence that rats are useful for forecasting human outcomes. The use of this model has brought a better understanding of the pathogeny and severity of alcohol-induced bone loss. Excessive intake of ethanol can cause bone loss⁶², increased adipose tissue in the bone marrow, altered numbers and activities of osteoblasts and osteoclasts, and increased apoptosis of bone cells, which can lead to secondary osteoporosis^{88,89}. At present, the ethyl alcohol model is only used to study the mechanisms of alcohol-induced osteoporosis.

(4) Disuse osteoporosis model

Disused osteoporosis models, which include surgical and non-surgical methods, are of great significance in the study of osteoporosis in paralysis, long-term postoperative bedridden cases, and aviation personnel^{90,91}. Surgical methods include denervation⁹², tendon removal and spinal cord resection. Non-operative methods include suspension⁹³, bandage binding and screw fixation. Rats have been extensively used as a model for disuse osteoporosis^{91–93}. Each of these seemingly disparate methods lead to similar skeletal changes, implying that the principal impacts on bone loss are due to pressure unloading. These models have been used to study the pathogeny of disuse osteoporosis rats in growth stages and maturity, as well as to evaluate the efficacy of potential interventions⁶². The results of Peng et al.⁵⁶ showed that, compared with a control group, the maximum load on the femoral neck was significantly reduced (27.7%, $P < 0.001$) and the energy absorption was significantly decreased (45.3%, $P < 0.001$) with immobilisation (IMM).

(5) Brain-derived osteoporosis model

The hypothalamo-pituitary gland system regulates the balance of several hormones, such as thyroid hormones (T3, T4), gonadotropins (LH, FSH), cortisol and leptin and insulin-like growth factor 1 (IGF-1). Hypothalamic-pituitary dissection (HPD) results in significant bone loss in sheep, affecting the trabeculae and cortical bone⁹⁴. Oheim et al.³⁰ showed significant trabeculae and cortical bone loss at 24 months after HPD in sheep. Histomorphometric analysis of the iliac crest showed a significant 60% reduction in BV/TV compared to the control group.

Melatonin secreted by the pineal gland can affect bone metabolism. A study by Egermann et al.²⁵ found that bone absorption increased after pineal resection (PX), and cancellous bone volume (BV/TV) decreased by – 13.3% six months later and decreased by – 21.5% if combined with OVX. Thirty months after surgery, there was still continuous bone loss. Although the degree of bone loss caused by this method is not up to the standard of OP (– 2.5SD), it can be used together with other methods in the construction of osteoporosis models. In addition, lateral ventricular injection of leptin significantly reduced left ventricular bone formation and resulted in significant trabecular loss in sheep³¹.

3.4.3 Combined osteoporosis Model

Due to the diversity in osteoporosis, a combined modelling method has great practical significance and application value. The combined modelling method not only simulates a variety of mechanisms of osteoporosis, but also has the advantages of a short modelling period and good modelling effect. It has therefore been favoured by many scholars. An osteoporosis model can shorten the modelling time by using other modelling methods combined with castration, such as castration + diet⁹⁵ and castration + glucocorticoids^{23,26–29,34,35,85}. Generally, the effect of combined modelling on bone mass, bone structure and biomechanical properties is more obvious than that of a single modelling method²³.

Discussion

In summary, there are many factors that cause osteoporosis. Different modelling methods can be chosen according to different causes of osteoporosis, and different animal models can be chosen according to different research directions, local animal ethical requirements, project funding and other factors. Most studies use rats for the construction of an osteoporosis model. We recommend 6–9 month old rats as an animal model for postmenopausal osteoporosis¹⁸ because the epiphysis of rats less than 6 months old has not been closed and the reduction of bone mass is not obvious¹⁹. Rats older than nine months will have the effect of ageing osteoporosis¹³. For some special studies, other animals can be chosen, such as knockout mice, and for fracture implants, other larger animals can be used. If the conditions permit, larger animals, such as rabbits, sheep, non-human primates and pigs, can be used in an animal model.

Conclusion

The exploration of osteoporosis has gradually matured. However, various experimental animals at present still have limitations and various modelling methods have their own emphasis. Animal models that have been produced can only show the characteristics of the disease in some aspects, such as aetiology, clinical symptoms, or pathophysiological changes. Each animal model has its own characteristics of osteoporosis. Researchers should, according

to their own research scope, define the content they want to study in the experimental design before initiating the experiment and select the appropriate modelling method to make it resemble experiences within clinical practices. With further development, more models will be reported and this will lay the foundation for a more comprehensive and thorough study of human osteoporosis.

List Of Abbreviations

BMC Bone mineral content

BMD Bone mineral density

FDA Food and Drug Administration

HPD Hypothalamic-pituitary dissection

SAM Senescence accelerated mice

OPG Osteoprotegerin

IMM Immobilisation

Declarations

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Availability of data and materials:

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Patient consent

No patient involved

Provenance and peer review

Not commissioned; externally peer reviewed.

data sharing statement

No additional data from this study are available.

Funding

The research is funded by Sichuan Provincial Administration of traditional Chinese Medicine, the project number is 2021MS454, and the special fund for 100 Talents Program of the First Affiliated Hospital of Chengdu University of TCM, the project number is 20-Y14.

Authors' contributions

Panyun Mu and Peihua Qu performed the search for the systematic review and extracted and prepared the data for the analysis. Yunlin Li and Jie Feng provides technical guidance for this system evaluation. Panyun Mu and Yimei Hu design and drafted the work. Yimei Hu substantively revised the work. The authors have revised the manuscript, read, and approved the final version.

Acknowledgements

Not applicable

References

1. Guo TM, Xing YL, Zhu HY, et al. Extracellular regulated kinase 5 mediates osteoporosis through modulating viability and apoptosis of osteoblasts in ovariectomized rats. *Biosci Rep* 2019;39(9) doi: 10.1042/BSR20190432 [published Online First: 2019/08/16]

2. Edwards MH, Dennison EM, Aihie Sayer A, et al. Osteoporosis and sarcopenia in older age. *Bone* 2015;80:126-30. doi: 10.1016/j.bone.2015.04.016 [published Online First: 2015/04/19]
3. Post TM, Cremers SC, Kerbusch T, et al. Bone physiology, disease and treatment: towards disease system analysis in osteoporosis. *Clinical pharmacokinetics* 2010;49(2):89-118. doi: 10.2165/11318150-000000000-00000 [published Online First: 2010/01/14]
4. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's Guide to Prevention and Treatment of Osteoporosis. *Osteoporos Int* 2014;25(10):2359-81. doi: 10.1007/s00198-014-2794-2 [published Online First: 2014/09/04]
5. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. *Osteoporos Int* 2006;17(12):1726-33. doi: 10.1007/s00198-006-0172-4 [published Online First: 2006/09/20]
6. Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. *J Bone Miner Res* 2016;31(1):16-35. doi: 10.1002/jbmr.2708 [published Online First: 2015/09/10]
7. Permuy M, Lopez-Pena M, Munoz F, et al. Rabbit as model for osteoporosis research. *J Bone Miner Metab* 2019;37(4):573-83. doi: 10.1007/s00774-019-01007-x [published Online First: 2019/05/16]
8. Bonucci E, Ballanti P. Osteoporosis-bone remodeling and animal models. *Toxicol Pathol* 2014;42(6):957-69. doi: 10.1177/0192623313512428 [published Online First: 2013/11/29]
9. Miller SC, Wronski TJ. Long-term osteopenic changes in cancellous bone structure in ovariectomized rats. *The Anatomical record* 1993;236(3):433-41. doi: 10.1002/ar.1092360303 [published Online First: 1993/07/01]
10. Anderson MP, Capen CC. Fine structural changes of bone cells in experimental nutritional osteodystrophy of green iguanas. *Virchows Archiv B, Cell pathology* 1976;20(3):169-84. doi: 10.1007/bf02890337 [published Online First: 1976/04/29]
11. Noor Z, Kania N, Setiawan B. Tibia bone properties at different time course of ovariectomized rats. *Journal of diabetes and metabolic disorders* 2014;13(1):91. doi: 10.1186/s40200-014-0091-4 [published Online First: 2014/10/16]
12. Fini M, Pierini G, Giavaresi G, et al. The ovariectomised sheep as a model for testing biomaterials and prosthetic devices in osteopenic bone: a preliminary study on iliac crest biopsies. *The International journal of artificial organs* 2000;23(4):275-81. [published Online First: 2000/06/01]
13. Keiler AM, Zierau O, Vollmer G, et al. Estimation of an early meaningful time point of bone parameter changes in application to an osteoporotic rat model with in vivo microcomputed tomography measurements. *Lab Anim* 2012;46(3):237-44. doi: 10.1258/la.2012.011154 [published Online First: 2012/06/23]
14. Ryu SJ, Ryu DS, Kim JY, et al. Bone Mineral Density Changes after Orchiectomy using a Scrotal Approach in Rats. *Korean J Spine* 2015;12(2):55-9. doi: 10.14245/kjs.2015.12.2.55 [published Online First: 2015/07/29]
15. Kreipke TC, Rivera NC, Garrison JG, et al. Alterations in trabecular bone microarchitecture in the ovine spine and distal femur following ovariectomy. *J Biomech* 2014;47(8):1918-21. doi: 10.1016/j.jbiomech.2014.03.025 [published Online First: 2014/04/12]
16. Wanderman NR, Mallet C, Giambini H, et al. An Ovariectomy-Induced Rabbit Osteoporotic Model: A New Perspective. *Asian Spine J* 2018;12(1):12-17. doi: 10.4184/asj.2018.12.1.12 [published Online First: 2018/03/06]
17. Sevil F, Kara ME. The effects of ovariectomy on bone mineral density, geometrical, and biomechanical characteristics in the rabbit femur. *Vet Comp Orthop Traumatol* 2010;23(1):31-6. doi: 10.3415/VCOT-08-09-0085 [published Online First: 2009/12/10]
18. Liu XL, Li CL, Lu WW, et al. Skeletal site-specific response to ovariectomy in a rat model: change in bone density and microarchitecture. *Clin Oral Implants Res* 2015;26(4):392-98. doi: 10.1111/clr.12360 [published Online First: 2014/03/07]
19. Lei Z, Xiaoying Z, Xingguo L. Ovariectomy-associated changes in bone mineral density and bone marrow haematopoiesis in rats. *Int J Exp Pathol* 2009;90(5):512-9. doi: 10.1111/j.1365-2613.2009.00661.x [published Online First: 2009/09/22]
20. Leitner MM, Tami AE, Montavon PM, et al. Longitudinal as well as age-matched assessments of bone changes in the mature ovariectomized rat model. *Lab Anim* 2009;43(3):266-71. doi: 10.1258/la.2008.008045 [published Online First: 2009/01/01]
21. Yang J, Pham SM, Crabbe DL. High-resolution micro-CT evaluation of mid- to long-term effects of estrogen deficiency on rat trabecular bone¹. *Academic Radiology* 2003;10(10):1153-58. doi: 10.1016/s1076-6332(03)00109-0
22. Jerome CP, Lees CJ, Weaver DS. Development of osteopenia in ovariectomized cynomolgus monkeys (*Macaca fascicularis*). *Bone* 1995;17(4 Suppl):403s-08s. doi: 10.1016/8756-3282(95)00318-8 [published Online First: 1995/10/01]
23. Schorlemmer S, Gohl C, Iwabu S, et al. Glucocorticoid treatment of ovariectomized sheep affects mineral density, structure, and mechanical properties of cancellous bone. *J Bone Miner Res* 2003;18(11):2010-5. doi: 10.1359/jbmr.2003.18.11.2010 [published Online First: 2003/11/11]
24. Shen V, Liang XG, Birchman R, et al. Short-term immobilization-induced cancellous bone loss is limited to regions undergoing high turnover and/or modeling in mature rats. *Bone* 1997;21(1):71-8. doi: 10.1016/s8756-3282(97)00070-7 [published Online First: 1997/07/01]
25. Egermann M, Gerhardt C, Barth A, et al. Pinealectomy affects bone mineral density and structure—an experimental study in sheep. *BMC musculoskeletal disorders* 2011;12:271. doi: 10.1186/1471-2474-12-271 [published Online First: 2011/11/26]
26. Goldhahn J, Jenet A, Schneider E, et al. Slow rebound of cancellous bone after mainly steroid-induced osteoporosis in ovariectomized sheep. *Journal of orthopaedic trauma* 2005;19(1):23-8. doi: 10.1097/00005131-200501000-00005 [published Online First: 2005/01/26]
27. Harrison KD, Hiebert BD, Panahifar A, et al. Cortical Bone Porosity in Rabbit Models of Osteoporosis. *J Bone Miner Res* 2020;35(11):2211-28. doi: 10.1002/jbmr.4124 [published Online First: 2020/07/03]
28. Castaneda S, Largo R, Calvo E, et al. Bone mineral measurements of subchondral and trabecular bone in healthy and osteoporotic rabbits. *Skeletal Radiol* 2006;35(1):34-41. doi: 10.1007/s00256-005-0022-z [published Online First: 2005/10/26]
29. Eschler A, Röpenack P, Herlyn PKE, et al. The standardized creation of a lumbar spine vertebral compression fracture in a sheep osteoporosis model induced by ovariectomy, corticosteroid therapy and calcium/phosphorus/vitamin D-deficient diet. *Injury* 2015;46:S17-S23. doi: 10.1016/s0020-

30. Oheim R, Beil FT, Kohne T, et al. Sheep model for osteoporosis: sustainability and biomechanical relevance of low turnover osteoporosis induced by hypothalamic-pituitary disconnection. *J Orthop Res* 2013;31(7):1067-74. doi: 10.1002/jor.22327 [published Online First: 2013/02/27]
31. Oheim R, Beil FT, Barvencik F, et al. Targeting the lateral but not the third ventricle induces bone loss in ewe: an experimental approach to generate an improved large animal model of osteoporosis. *J Trauma Acute Care Surg* 2012;72(3):720-6. doi: 10.1097/TA.0b013e318238b3bd [published Online First: 2012/04/12]
32. Castaneda S, Calvo E, Largo R, et al. Characterization of a new experimental model of osteoporosis in rabbits. *J Bone Miner Metab* 2008;26(1):53-9. doi: 10.1007/s00774-007-0797-1 [published Online First: 2007/12/21]
33. Kielbowicz Z, Piatek A, Kurocka P, et al. Experimental osteoporosis in sheep—mechanical and histological approach. *Pol J Vet Sci* 2016;19(1):109-18. doi: 10.1515/pjvs-2016-0014 [published Online First: 2016/04/21]
34. Cabrera D, Wolber FM, Dittmer K, et al. Glucocorticoids affect bone mineral density and bone remodelling in OVX sheep: A pilot study. *Bone Rep* 2018;9:173-80. doi: 10.1016/j.bonr.2018.11.001 [published Online First: 2018/11/28]
35. Muller R, Henss A, Kampschulte M, et al. Analysis of microscopic bone properties in an osteoporotic sheep model: a combined biomechanics, FE and ToF-SIMS study. *J R Soc Interface* 2019;16(151):20180793. doi: 10.1098/rsif.2018.0793 [published Online First: 2019/04/09]
36. Xiao W, Beibei F, Guangsi S, et al. Iron overload increases osteoclastogenesis and aggravates the effects of ovariectomy on bone mass. *The Journal of endocrinology* 2015;226(3):121-34. doi: 10.1530/joe-14-0657 [published Online First: 2015/06/28]
37. Hanyu T, Chotanaphuti T, Arai K, et al. Histomorphometric assessment of bone changes in rats with type II collagen-induced arthritis. *Bone* 1999;24(5):485-90. doi: 10.1016/s8756-3282(99)00006-x [published Online First: 1999/05/13]
38. Nakano A, Kanda T, Abe H. Bone changes and mineral metabolism disorders in rats with experimental liver cirrhosis. *Journal of gastroenterology and hepatology* 1996;11(12):1143-54. doi: 10.1111/j.1440-1746.1996.tb01843.x [published Online First: 1996/12/01]
39. Stolzing A, Sellers D, Llewelyn O, et al. Diabetes induced changes in rat mesenchymal stem cells. *Cells Tissues Organs* 2010;191(6):453-65. doi: 10.1159/000281826 [published Online First: 2010/02/05]
40. Isomura H, Fujie K, Shibata K, et al. Bone metabolism and oxidative stress in postmenopausal rats with iron overload. *Toxicology* 2004;197(2):93-100. doi: 10.1016/j.tox.2003.12.006 [published Online First: 2004/03/09]
41. Schulz MC, Kowald J, Estenfelder S, et al. Site-Specific Variations in Bone Mineral Density under Systemic Conditions Inducing Osteoporosis in Minipigs. *Frontiers in Physiology* 2017;8 doi: 10.3389/fphys.2017.00426
42. Fleming A, Sato M, Goldsmith P. High-Throughput In Vivo Screening for Bone Anabolic Compounds with Zebrafish. *Journal of Biomolecular Screening* 2005;10(8):823-31. doi: 10.1177/1087057105279952
43. Lin S, Huang J, Zheng L, et al. Glucocorticoid-induced osteoporosis in growing rats. *Calcif Tissue Int* 2014;95(4):362-73. doi: 10.1007/s00223-014-9899-7 [published Online First: 2014/08/05]
44. Amanzadeh J, Gitomer WL, Zerwekh JE, et al. Effect of high protein diet on stone-forming propensity and bone loss in rats. *Kidney international* 2003;64(6):2142-9. doi: 10.1046/j.1523-1755.2003.00309.x [published Online First: 2003/11/25]
45. Matsushita M, Tsuboyama T, Kasai R, et al. Age-related changes in bone mass in the senescence-accelerated mouse (SAM). SAM-R/3 and SAM-P/6 as new murine models for senile osteoporosis. *The American journal of pathology* 1986;125(2):276-83. [published Online First: 1986/11/01]
46. Wu DD, Boyd RD, Fix TJ, et al. Regional patterns of bone loss and altered bone remodeling in response to calcium deprivation in laboratory rabbits. *Calcif Tissue Int* 1990;47(1):18-23. doi: 10.1007/bf02555861 [published Online First: 1990/07/01]
47. Ferretti M, Cavani F, Smargiassi A, et al. Mineral and Skeletal Homeostasis Influence the Manner of Bone Loss in Metabolic Osteoporosis due to Calcium-Deprived Diet in Different Sites of Rat Vertebra and Femur. *Biomed Res Int* 2015;2015:304178. doi: 10.1155/2015/304178 [published Online First: 2015/06/13]
48. Rude RK, Gruber HE, Wei LY, et al. Magnesium deficiency: effect on bone and mineral metabolism in the mouse. *Calcif Tissue Int* 2003;72(1):32-41. doi: 10.1007/s00223-001-1091-1 [published Online First: 2002/10/09]
49. Aguado E, Mabileau G, Goyenvallé E, et al. Hypodynamia Alters Bone Quality and Trabecular Microarchitecture. *Calcif Tissue Int* 2017;100(4):332-40. doi: 10.1007/s00223-017-0235-x [published Online First: 2017/02/06]
50. Jiang SD, Yang YH, Chen JW, et al. Isolated osteoblasts from spinal cord-injured rats respond less to mechanical loading as compared with those from hindlimb-immobilized rats. *J Spinal Cord Med* 2013;36(3):220-4. doi: 10.1179/2045772312Y.0000000071 [published Online First: 2013/07/03]
51. Chen H, Zhou X, Emura S, et al. Site-specific bone loss in senescence-accelerated mouse (SAMP6): a murine model for senile osteoporosis. *Exp Gerontol* 2009;44(12):792-8. doi: 10.1016/j.exger.2009.09.009 [published Online First: 2009/10/10]
52. Dick IM, St John A, Heal S, et al. The effect of estrogen deficiency on bone mineral density, renal calcium and phosphorus handling and calcitropic hormones in the rat. *Calcif Tissue Int* 1996;59(3):174-8. doi: 10.1007/s002239900105 [published Online First: 1996/09/01]
53. Huang L, You YK, Zhu TY, et al. Validity of leptin receptor-deficiency (db/db) type 2 diabetes mellitus mice as a model of secondary osteoporosis. *Sci Rep* 2016;6:27745. doi: 10.1038/srep27745 [published Online First: 2016/06/11]
54. Kurth AA, Müller R. The effect of an osteolytic tumor on the three-dimensional trabecular bone morphology in an animal model. *Skeletal Radiol* 2001;30(2):94-8. doi: 10.1007/s002560000287 [published Online First: 2001/04/20]
55. Melville KM, Kelly NH, Khan SA, et al. Female mice lacking estrogen receptor-alpha in osteoblasts have compromised bone mass and strength. *J Bone Miner Res* 2014;29(2):370-9. doi: 10.1002/jbmr.2082 [published Online First: 2013/09/17]

56. Peng Z, Tuukkanen J, Zhang H, et al. The mechanical strength of bone in different rat models of experimental osteoporosis. *Bone* 1994;15(5):523-32. doi: 10.1016/8756-3282(94)90276-3 [published Online First: 1994/09/01]
57. Sigrist IM, Gerhardt C, Alini M, et al. The long-term effects of ovariectomy on bone metabolism in sheep. *J Bone Miner Metab* 2007;25(1):28-35. doi: 10.1007/s00774-006-0724-x [published Online First: 2006/12/26]
58. Scholz-Ahrens KE, Dellling G, Stampa B, et al. Glucocorticosteroid-induced osteoporosis in adult primiparous Gottingen miniature pigs: effects on bone mineral and mineral metabolism. *Am J Physiol Endocrinol Metab* 2007;293(1):E385-95. doi: 10.1152/ajpendo.00627.2006 [published Online First: 2007/04/26]
59. Reinwald S, Burr D. Review of nonprimate, large animal models for osteoporosis research. *J Bone Miner Res* 2008;23(9):1353-68. doi: 10.1359/jbmr.080516 [published Online First: 2008/05/29]
60. Jilka RL. The relevance of mouse models for investigating age-related bone loss in humans. *J Gerontol A Biol Sci Med Sci* 2013;68(10):1209-17. doi: 10.1093/gerona/glt046 [published Online First: 2013/05/22]
61. Costa LA, Lopes BF, Lanis AB, et al. Bone demineralization in the lumbar spine of dogs submitted to prednisone therapy. *J Vet Pharmacol Ther* 2010;33(6):583-6. doi: 10.1111/j.1365-2885.2010.01174.x [published Online First: 2010/11/11]
62. Komori T. Animal models for osteoporosis. *Eur J Pharmacol* 2015;759:287-94. doi: 10.1016/j.ejphar.2015.03.028 [published Online First: 2015/03/31]
63. Yao W, Hadi T, Jiang Y, et al. Basic fibroblast growth factor improves trabecular bone connectivity and bone strength in the lumbar vertebral body of osteopenic rats. *Osteoporos Int* 2005;16(12):1939-47. doi: 10.1007/s00198-005-1969-2 [published Online First: 2005/08/09]
64. Colman RJ. Non-human primates as a model for aging. *Biochim Biophys Acta Mol Basis Dis* 2018;1864(9 Pt A):2733-41. doi: 10.1016/j.bbdis.2017.07.008 [published Online First: 2017/07/22]
65. Lucinda LM, Vieira BJ, Oliveira TT, et al. Evidences of osteoporosis improvement in Wistar rats treated with Ginkgo biloba extract: a histomorphometric study of mandible and femur. *Fitoterapia* 2010;81(8):982-7. doi: 10.1016/j.fitote.2010.06.014 [published Online First: 2010/07/06]
66. Gilsanz V, Roe TF, Gibbens DT, et al. Effect of sex steroids on peak bone density of growing rabbits. *The American journal of physiology* 1988;255(4 Pt 1):E416-21. doi: 10.1152/ajpendo.1988.255.4.E416 [published Online First: 1988/10/01]
67. Smith SY, Jolette J, Turner CH. Skeletal health: primate model of postmenopausal osteoporosis. *American journal of primatology* 2009;71(9):752-65. doi: 10.1002/ajp.20715 [published Online First: 2009/06/06]
68. Zhao H, Li X, Zhang D, et al. Integrative Bone Metabolomics-Lipidomics Strategy for Pathological Mechanism of Postmenopausal Osteoporosis Mouse Model. *Sci Rep* 2018;8(1):16456. doi: 10.1038/s41598-018-34574-6 [published Online First: 2018/11/09]
69. Turner RT. Mice, estrogen, and postmenopausal osteoporosis. *J Bone Miner Res* 1999;14(2):187-91. doi: 10.1359/jbmr.1999.14.2.187 [published Online First: 1999/02/05]
70. Thompson DD, Simmons HA, Pirie CM, et al. FDA Guidelines and animal models for osteoporosis. *Bone* 1995;17(4 Suppl):125s-33s. doi: 10.1016/8756-3282(95)00285-1 [published Online First: 1995/10/01]
71. Yousefzadeh N, Kashfi K, Jeddi S, et al. Ovariectomized rat model of osteoporosis: a practical guide. *EXCLI J* 2020;19:89-107. doi: 10.17179/excli2019-1990 [published Online First: 2020/02/11]
72. Maenz S, Brinkmann O, Hasenbein I, et al. The old sheep: a convenient and suitable model for senile osteopenia. *J Bone Miner Metab* 2020;38(5):620-30. doi: 10.1007/s00774-020-01098-x [published Online First: 2020/04/17]
73. Hambright WS, Niedernhofer LJ, Huard J, et al. Murine models of accelerated aging and musculoskeletal disease. *Bone* 2019;125:122-27. doi: 10.1016/j.bone.2019.03.002 [published Online First: 2019/03/08]
74. Azuma K, Zhou Q, Kubo KY. Morphological and molecular characterization of the senile osteoporosis in senescence-accelerated mouse prone 6 (SAMP6). *Med Mol Morphol* 2018;51(3):139-46. doi: 10.1007/s00795-018-0188-9 [published Online First: 2018/04/06]
75. Chen H, Emura S, Yao XF, et al. Morphological study of the parathyroid gland and thyroid C cell in senescence-accelerated mouse (SAMP6), a murine model for senile osteoporosis. *Tissue Cell* 2004;36(6):409-15. doi: 10.1016/j.tice.2004.07.002 [published Online First: 2004/11/10]
76. Chen H, Yao XF, Emura S, et al. Morphological changes of skeletal muscle, tendon and periosteum in the senescence-accelerated mouse (SAMP6): a murine model for senile osteoporosis. *Tissue Cell* 2006;38(5):325-35. doi: 10.1016/j.tice.2006.08.001 [published Online First: 2006/10/03]
77. Azzu V, Valencak TG. Energy Metabolism and Ageing in the Mouse: A Mini-Review. *Gerontology* 2017;63(4):327-36. doi: 10.1159/000454924 [published Online First: 2017/01/25]
78. Watanabe K, Hishiya A. Mouse models of senile osteoporosis. *Mol Aspects Med* 2005;26(3):221-31. doi: 10.1016/j.mam.2005.01.006 [published Online First: 2005/04/07]
79. Mitchell SJ, Scheibye-Knudsen M, Longo DL, et al. Animal models of aging research: implications for human aging and age-related diseases. *Annu Rev Anim Biosci* 2015;3:283-303. doi: 10.1146/annurev-animal-022114-110829 [published Online First: 2015/02/18]
80. Takeda T, Hosokawa M, Takeshita S, et al. A new murine model of accelerated senescence. *Mechanisms of ageing and development* 1981;17(2):183-94. doi: 10.1016/0047-6374(81)90084-1 [published Online First: 1981/10/01]
81. Kanzaki S, Ito M, Takada Y, et al. Resorption of auditory ossicles and hearing loss in mice lacking osteoprotegerin. *Bone* 2006;39(2):414-9. doi: 10.1016/j.bone.2006.01.155 [published Online First: 2006/03/28]
82. Al Anouti F, Taha Z, Shamim S, et al. An insight into the paradigms of osteoporosis: From genetics to biomechanics. *Bone Rep* 2019;11:100216. doi: 10.1016/j.bonr.2019.100216 [published Online First: 2019/08/03]
83. Boudin E, Fijalkowski I, Hendrickx G, et al. Genetic control of bone mass. *Mol Cell Endocrinol* 2016;432:3-13. doi: 10.1016/j.mce.2015.12.021 [published Online First: 2016/01/10]

84. Luo J, Sun P, Siwko S, et al. The role of GPCRs in bone diseases and dysfunctions. *Bone Res* 2019;7:19. doi: 10.1038/s41413-019-0059-6 [published Online First: 2019/10/28]
85. Fu D, Lin T, Liu J, et al. Relation between the development of osteoporosis and osteonecrosis following glucocorticoid in a rabbit model. *Indian Journal of Orthopaedics* 2016;50(4) doi: 10.4103/0019-5413.185606
86. Oršolić N, Goluža E, Dikić D, et al. Role of flavonoids on oxidative stress and mineral contents in the retinoic acid-induced bone loss model of rat. *European journal of nutrition* 2014;53(5):1217-27. doi: 10.1007/s00394-013-0622-7 [published Online First: 2013/11/26]
87. Allen SP, Maden M, Price JS. A role for retinoic acid in regulating the regeneration of deer antlers. *Developmental biology* 2002;251(2):409-23. doi: 10.1006/dbio.2002.0816 [published Online First: 2002/11/19]
88. Maurel DB, Boisseau N, Benhamou CL, et al. Alcohol and bone: review of dose effects and mechanisms. *Osteoporos Int* 2012;23(1):1-16. doi: 10.1007/s00198-011-1787-7 [published Online First: 2011/09/20]
89. Luo Z, Liu Y, Liu Y, et al. Cellular and molecular mechanisms of alcohol-induced osteopenia. *Cell Mol Life Sci* 2017;74(24):4443-53. doi: 10.1007/s00018-017-2585-y [published Online First: 2017/07/05]
90. Giangregorio L, Blimkie CJ. Skeletal adaptations to alterations in weight-bearing activity: a comparison of models of disuse osteoporosis. *Sports medicine (Auckland, NZ)* 2002;32(7):459-76. doi: 10.2165/00007256-200232070-00005 [published Online First: 2002/05/23]
91. Shirazi-Fard Y, Metzger CE, Kwaczala AT, et al. Moderate intensity resistive exercise improves metaphyseal cancellous bone recovery following an initial disuse period, but does not mitigate decrements during a subsequent disuse period in adult rats. *Bone* 2014;66:296-305. doi: 10.1016/j.bone.2014.06.005 [published Online First: 2014/06/15]
92. Turner RT, Bell NH. The effects of immobilization on bone histomorphometry in rats. *J Bone Miner Res* 1986;1(5):399-407. doi: 10.1002/jbmr.5650010504 [published Online First: 1986/10/01]
93. Wronski TJ, Morey ER. Skeletal abnormalities in rats induced by simulated weightlessness. *Metabolic bone disease & related research* 1982;4(1):69-75. doi: 10.1016/0221-8747(82)90011-x [published Online First: 1982/01/01]
94. Oheim R, Beil FT, Krause M, et al. Mandibular bone loss in ewe induced by hypothalamic-pituitary disconnection. *Clin Oral Implants Res* 2014;25(11):1239-44. doi: 10.1111/clr.12259 [published Online First: 2013/10/10]
95. Sipos W, Kralicek E, Rauner M, et al. Bone and cellular immune system of multiparous sows are insensitive to ovariectomy and nutritive calcium shortage. *Horm Metab Res* 2011;43(6):404-9. doi: 10.1055/s-0031-1277154 [published Online First: 2011/05/11]

Table

Table 1
Table of general characteristics of the included English studies

Reference	Animal	Animal Model(Duration)	Animal No.	Outcome measures		
				BMD Location	BMD measurement	Others
Guo,2019	Rats	OVX + ERK-5 (8 weeks post-operatively)	60	femurs	DXA	Ca,P,ALP,Three-point bending test,biomechanical
Lin,2020	rabbit	GC (2,4,8 weeks post-operatively)	56	femurs	DXA	Tb.Th,Tb.Sp,Tb.N,BS/BV,BV/TV,Ca,P,TC,TG
Hui,2018	Rats	exposed to silica (24 weeks)	12	femurs,tibia	micro-CT	Tb.Th,Tb.Sp,Tb.N,SMI,Ca,P,PTH,25-(OH)-D,etc.
Liu,2014	Rats	OVX (2, 4, 12, 24 and 36weeks post-surgery)	33	whole body	micro-CT	~
Huang,2016	Rats	crp + db/db (36 weeks)	33	tibia	micro-CT	SMI,Tb.Th,Tb.Sp,Tb.N
Egermann,2011	sheeps	OVX + Px (before and 3, 9, 18 and 30 months after surgery)	26	distal radius	pQCT	Tb.Th,Tb.Sp,Tb.N,BS/BV,BV/TV,bone histological markers
Stendig-Lindberg,2014	Rats	Mg (12 months)	16	femurs, lumbar	DXA	BV/TV,,TBPf,Mg ,etc.
Oheim,2012	sheeps	OVX + CSF/Leptin-LV/Leptin-TV (3 mouths)	16	no	no	BV/TV
Schulz,2017	pigs	Prednisolone (before and after 6,9 mouths)	37	lumbar, mandible and maxilla	QCT	serum parameters
Goldhahn,2005	sheeps	OVX + MP (before OVX and after 12, 17, 22, 27, and 40 weeks)	18	distal radius	pQCT	BV/TV,BS/BV,Tb.Th,Tb.Sp,Tb.N,SMI
Oheim,2013	sheeps	OVX + HPD (12,24 mouths after surgery)	5	no	no	BV/TV,Tb.Th,Tb.Sp,Tb.N,Histomorphometry,Biom Testing,etc.
Kurth,2001	Rats	W256 (28 days after surgery)	30	no	no	ctBMC,tBMC,BV/TV,BS/BV,Tb.Th,Tb.Sp,Tb.N
Eschler,2005	sheeps	OVX + DEX (5.5 mouths)	24	distal radius,lumbar	pQCT	BV/TV,Tb.Th,Tb.Sp,Tb.N,SMI
Chen,2009	mice	SAMP6 (5,12 mouths)	32	femurs,tibia, lumbar	micro-CT	BV/TV,Tb.Th,Tb.Sp,Tb.N,TBPf,SMI,etc.
Shen,1997	Rats	OVX,LoCa,IM (4 weeks)	84	no	no	BV/TV,Tb.Th,Tb.Sp,Tb.N,etc.
Wu,1990	rabbit	LoCa (14 weeks)	10	no	no	Ca,PBMC,Tb.Th,Tb.N,etc.
Dick,1996	Rats	OOX (1,3,6 weeks after surgery)	36	Global,femurs, lumbar	DXA	BMC
Sevil,2010	rabbit	OVX (8 and 16 weeks after surgery)	24	femurs	DXA	BMC,BA,weight,femur(Cortical thickness,Diamete bending
Peng,1994	Rats	OVX (6 weeks),IMM(3 weeks)	97	no	no	Weight,Ash weight,ash weight/body weight, bone femur,Stress and strain,diameter, conical bone area marrow area
Fini,2000	Rats	OVX (12 and 24 months after surgery)	12	no	no	BV/TV,Ce.V/TV,Tb.Th,Tb.Sp,Tb.N, O.Th,OV/TV,MA BFR/BS,Aj.AR,Mlt, Omt

Reference	Animal	Animal Model(Duration)	Animal No.	Outcome measures		
				BMD Location	BMD measurement	Others
Noor,2014	Rats	OVX (4,8 weeks after surgery)	30	no	no	BV/TV,Tb.Th,Tb.Sp,Tb.N,CTX,bone mineral elements Zn, Ni, Ca/P, Cu/Zn),
Maisushita,1986	mice	SAM (4 or 5 months of age)	229	no	no	femur(Ca,P),HYP
Wanderman,2018	rabbit	OVX (17 weeks postoperatively)	36	tibia,femur	DXA	weight
Kreipke,2014	sheep	OVX (12,24 months after surgery)	13	vertebral,femur	μ-CT	BV/TV,TMD,SMI,Tb.Sp,Tb.Th,DA
Muller,2019	sheep	OVX,O + Lo.Ca,O + Lo.Ca + GLU (8 months)	28	lumbar	DXA	BV/TV,BS/BV,Tb.Th,Tb.Sp,Tb.N,SMI,etc.
Sipos,2011	sows	OVX + Lo.Ca (10 months)	32	femur	DXA	BV/TV,BS/BV,Tb.N,Tb.Th,Tb.Sp,DA, ConnDens,SM Biochemical bone marker ,etc.
Nakano,1996	rats	CCI4 + TAA (8, 12 and 24 weeks after start)	126	no	no	Histomorphometric parameters,Biological parameters,parameters,Bone mineral metabolism parameters
Isomura,2003	rats	iron lactate (4 weeks after diets)	48	no	no	weights,ALP,Ca,P,Fe,Osteocalcin,Osteopontin,Deo
Ryu,2015	rats	OCX (8,10 weeks post-surgery)	20	femur	MicroCT	~
Castañeda,2006	rabbits	OVX + corticosteroid (4 weeks after surgery)	29	lumbar,knee,tibia	DXA	BA,BMC
Xiao,2014	rats	STZ (4, 8, 12, and 16 weeks after first injection of STZ)	140	no	no	Ca,P,AKP,BGP
Li,2018	rabbits	OVX + MP (6,10 weeks after surgery)	32	lumbar	MicroCT	weight,BMD,BV/TV,BS/BV,Tb.Th,Tb.Sp,Tb.N,etc.
Harrison,2020	rabbits	OVX,GC,OVX + GC,PTH(12 weeks)	35	no	no	BV/TV,Tb.Th,Tb.Sp,Tb.N,etc.
Stolzing,2010	rats	STZ (1,4,12weeks)	8	tibia	MicroCT	BV/TV,BS/BV,Tb.Th,Tb.Sp,Tb.N,etc.
Amanzadeh,2003	rats	casein-diet (60 days)	36	no	no	Bone histomorphometry,Serum biochemistry,Urinary factors,etc.
Maryin,1976	Beagle Dogs	Lo.Ca + Lo.P (6 ~ 16months)	15	no	no	Ca,P,Mg,etc.
Keiler,2012	rats	OVX (10 weeks after surgery)	8	tibia,lumbar	MicroCT	BV/TV,Tb.Th,Tb.Sp,Tb.N,Conn.D
Melville,2014	mice	Transgene (4, 8, 12, and 18 weeks of age)	33	tibia,femur,lumbar	MicroCT	BV/TV,Tb.Th,Tb.Sp,etc.
Schorlemmer,2003	sheep	OVX,OVX + GLU (12 months)	16	tibial,lumbar	pQCT	BV/TV,BS/BV,Tb.Th,Tb.Sp,Tb.N,ON/BV,OS/BS
Lin,2014	rats	GLU (3 months)	36	lumbar,femur	DXA	BMC,MA,SMI,BV/TV,Tb.Th,Tb.N,Tb.Sp,etc.
Cabrera,2018	sheep	OVX + GLU (5 months after surgery)	28	lumbar,femur,tibia	DXA + pQCT	BMC,OC,CTX-1

Reference	Animal	Animal Model(Duration)	Animal No.	Outcome measures		
				BMD Location	BMD measurement	Others
Yang,2003	rats	OVX (6,16 weeks after surgery)	28	tibial	MicroCT	BV/TV,Tb.Th,Tb.Sp,SMI
Fleming,2005	zebrafish	skeletal staining (6 days)	15	no	no	vitamin D3analogs,PTH
Hanyu,1999	rats	bovine type II collagen (4,6,14 weeks)	35	no	no	BV/TV,Tb.Th,Tb.N,OV/TV,etc.
Aguado,2017	chicken	Limit movement (53 days of age)	20	no	no	BV/TV,Tb.Th,Tb.Sp,Tb.N,SMI,Tb.Pf
Wang,2015	mice	OVX,OVX + Fe (2 months for feed)	24	no	no	AKP,TRAPROS,BV/TV,Tb.Th,Tb.Sp,Tb.Pf,SMI,RUN
Jiang,2013	rats	SCI,hindlimb cast-immobilized (3 weeks)	18	no	no	weight,ALPase activity, PICP and osteocalcin,Run
Leitner,2009	rats	OVX (4weeks for surgery,4 weeks after surgery been euthanized)	21	femur	pQCT + MicroCT	BV/TV,VOI
Miller,1993	rats	OVX (18 mouths after surgery)	24	no	no	Type and length of trabecular struts,Marrow star
Rude,2003	mice	diet-lo.Mg (1 ~ 6 weeks)	23	no/femmur,tibia	no	serum Mg, Ca, PTH,and/or TNFa,Ash(Mg,Ca,P),Hi indices(BV/TV,etc.)
Oheim,2014	sheep	OVX + HPD (6 mouths)	10	no	no	Histomorphometry(BV/TV,Tb.Th,Tb.N,Tb.Sp,OV/E
Ferretti,2015	rats	lo.Ca + PTH (4 weeks for feed)	18	no	no	BV/TV,Tb.Th,Tb.Sp,Tb.N,Ct.Th,Ct-B-Ar,Ca,P,OPG,B
Zhu,2009	rats	OVX (4, 8 and 12 weeks post operation)	30	femur	DXA	VHT,VAT,VTB,MKC.N,OB.N,OC.N,MC.N
Jerome,1995	monkeys	OVX (before and 1 year after surgery)	38	lumbar	DXA	BMC,Radiographic examination of growth plates
Kielbowicz,2016	sheep	OVX + SC-methylprednisolone (20 weeks)	49	no	no	C,Ca,O,Na,Mg,P,Mechanical tests,etc.
Castañeda,2008	rabbits	OVX + MPH (6,16 weeks after surgery)	35	lumbar,left knee	DXA	CV,MRI,glucose, total cholesterol, triglyceride, oest
Aota,2013	chicken	PNX (6,10 days after surgery)	120	no	no	BV/TV,Tb.Th,Tb.Sp,Tb.N,BRs.R,Dynamic paramet bone,Parameters in endochondral ossification an plate

Figures




Figure 1

Flowchart of Literature Selection

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [PRISMA2020checklist.docx](#)